How to Submit a Postmarketing Safety Report to FDA
Apply the right US reporting clock to the right product class, and evidence the submission.
What a how-to is not
A how-to is SPEQ’s practitioner method, not a procedure. It does not replace your own SOP, it is not a validated approach, and the judgement calls in it belong to your quality unit.
US postmarketing safety reporting for drugs and for biological products runs on parallel regimes with the same architecture: expedited reports for serious and unexpected reactions, and periodic reports for everything else. The recurring error is not a missed case but a misapplied regime — the reporting rule that governs a biological product is not the one that governs a drug, and a device is elsewhere entirely.
- 1
Confirm which regime governs the product
Establish the product class before anything else, because the applicable reporting provision follows from it. Applying the drug provision to a biological product, or either to a device, produces reports that are late or misdirected even when the underlying assessment was sound.
- 2
Determine seriousness and expectedness
Assess seriousness against the regulatory definition and expectedness against the approved labelling. A reaction that is both serious and unexpected is an expedited alert report, due as soon as possible and no later than 15 calendar days from the applicant’s initial receipt of the information; everything else flows into periodic reporting.
- 3
Establish the awareness date
Record when the applicant first received information meeting the reporting criteria, and from whom. This date starts the clock, and it must be evidenced from the intake record rather than reconstructed from the case file.
- 4
Investigate promptly and pursue follow-up
Investigate reports of serious reactions and seek the information needed to assess them. Follow-up to an expedited alert report carries its own 15-calendar-day clock from receipt of the new information, or runs to whatever date the agency specifies when it asks — it is not the remainder of the original window.
- 5
Route the remainder into periodic reports
Cases that are not both serious and unexpected are reported periodically: quarterly for the first three years after approval, annually thereafter. A periodic report is a different cadence, not a lower standard, and its contents must reconcile to the same safety database.
- 6
Submit electronically and keep the acknowledgement
Transmit in the required electronic format to the appropriate centre and retain the acknowledgement. The acknowledgement, not the internal completion status, is the evidence that submission occurred.
- 7
Reconcile submissions against the safety database
Periodically reconcile what the database says should have been submitted against what was acknowledged. Reconciliation is how late or failed transmissions are found before an inspector finds them.
- !Applying the drug reporting provision to a biological product, or either to a device — three different regimes.
- !Expectedness judged against a draft or superseded label rather than the approved labelling.
- !Awareness date taken from case file creation rather than from the documented intake record.
- !The periodic cadence left at annual through the first three years after approval, when quarterly applies.
- !No routine reconciliation between the safety database and transmission acknowledgements.
How to Submit a Postmarketing Safety Report to FDA: frequently asked questions
Common questions on submit a postmarketing safety report to fda.
Why do drugs and biological products have separate reporting provisions?
They are authorised under different frameworks, and their postmarketing reporting obligations are set out separately as a result. The architecture is similar enough to invite substitution and different enough that substituting one for the other is a genuine compliance error.
What makes a reaction unexpected?
That its nature, severity, specificity or outcome is not consistent with the approved labelling. Unexpectedness is a labelling comparison, not a clinical surprise — a well-known reaction absent from your approved label is still unexpected for reporting purposes.
Does a follow-up report restart the clock?
Follow-up information that materially changes the assessment carries its own promptness obligation from the date it is received. It is not a second chance at the original deadline, and a case that became reportable only on follow-up is timed from that new awareness.